Detalles de la búsqueda
1.
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma.
Blood
; 143(7): 592-596, 2024 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38048557
2.
Tγδ LGLL identifies a subset with more symptomatic disease: analysis of an international cohort of 137 patients.
Blood
; 141(9): 1036-1046, 2023 03 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36096473
3.
Pro-inflammatory cells sustain leukemic clonal expansion in T-cell large granular lymphocyte leukemia.
Haematologica
; 109(1): 163-174, 2024 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37439335
4.
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials.
Haematologica
; 109(1): 245-255, 2024 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37439329
5.
A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group.
Ann Hematol
; 103(1): 125-132, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37731147
6.
Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis.
Haematologica
; 108(3): 833-842, 2023 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36200419
7.
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.
Hematol Oncol
; 40(4): 704-715, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35608183
8.
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Lancet Oncol
; 22(12): 1705-1720, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34774221
9.
Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice.
Cancer
; 127(12): 2015-2024, 2021 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33739457
10.
Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse.
Br J Haematol
; 188(6): 907-917, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31898319
11.
Identification of a miR-146b-Fas ligand axis in the development of neutropenia in T large granular lymphocyte leukemia.
Haematologica
; 105(5): 1351-1360, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31467122
12.
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials.
Haematologica
; 105(4): 1074-1080, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31248973
13.
Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation.
Hematol Oncol
; 38(3): 257-265, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32356913
14.
Neurolymphomatosis, a rare manifestation of peripheral nerve involvement in lymphomas: Suggestive features and diagnostic challenges.
J Peripher Nerv Syst
; 25(3): 312-315, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32627254
15.
Interrogating molecular genetics to refine LGLL classification.
Blood
; 139(20): 3002-3004, 2022 05 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-35587872
16.
Whole-body low-dose CT recognizes two distinct patterns of lytic lesions in multiple myeloma patients with different disease metabolism at PET/MRI.
Ann Hematol
; 98(3): 679-689, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-30539276
17.
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma.
Blood
; 127(9): 1102-8, 2016 Mar 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-26729895
18.
Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine-Results from the Italian 'Back to Life' project.
Qual Life Res
; 27(6): 1545-1554, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29520559
19.
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials.
Haematologica
; 106(1): 291-294, 2021 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32107338
20.
Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study.
Ann Hematol
; 95(7): 1107-14, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-27103007